Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PAM | P19021 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | USP5 | P45974 | 1/20 | 0.44 |
| ▸ | USP4 | Q13107 | 1/20 | 0.44 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31239081 | 0.90 | CYP19A1 (0.64) | CYP19A1SMN1; SMN2L3MBTL1ALDH1A1LMNA | |
| SCHEMBL27811093 | 0.84 | TSHR (0.41) | CYP19A1SMN1; SMN2L3MBTL1ALDH1A1POLB | |
| SCHEMBL11561793 | 0.83 | RAB9A (0.47) | SMN1; SMN2MAPK1ALDH1A1POLBTSHR | |
| SCHEMBL240908 | 0.82 | TSHR (0.45) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL29184630 | 0.81 | KMT2A (0.53) | ALDH1A1KMT2ACES1GAA | |
| SCHEMBL969754 | 0.81 | TSHR (0.42) | SMN1; SMN2L3MBTL1ALDH1A1TSHRLMNA | |
| SCHEMBL7414860 | 0.79 | TSHR (0.40) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR | |
| SCHEMBL4996914 | 0.79 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL30571184 | 0.79 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL6245082 | 0.79 | TSHR (0.40) | SMN1; SMN2L3MBTL1ALDH1A1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103080064-A | Process for producing carboxylic acid ester | SUMITOMO CHEMICAL CO | 2013-05-01 | — | — | CN | disclosed |
| US-7883713-B2 | Suspension, ointment, solution, spray, lotion, gel, cream, powder, powder spray, paste, emulsion, foam or stick; for treatment of herpes infections in humans | AICURIS GMBH & CO. KG (DE) | 2011-02-08 | — | — | US | disclosed |
| US-7105553-B2 | Thiazolyl amide derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| CN-1253441-C | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2006-04-26 | — | — | CN | disclosed |
| US-20040235916-A1 | Thiazolyl amides and their use as antiviral drugs | SCHOHE-LOOP RUDOLF (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040235917-A1 | Topical application of thiazolyl amides | AIC316 GMBH (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040006076-A1 | Thiazolyl amide derivatives | AICURIS GMBH & CO. KG (DE) | 2004-01-08 | — | — | US | disclosed |
| CN-1304447-A | Treatment of parasitic diseases by inhibition of cysteine proteases of papain superfamily | SMITHKLINE BEECHAM CORP (US) | 2001-07-18 | — | — | CN | disclosed |
| CN-1255119-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2000-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235916-A1 | Thiazolyl amides and their use as antiviral drugs | EIF2AK2, MAVS, ZC3HAV1 | CYP19A1 3215/4885SMN1; SMN2 4321/4885L3MBTL1 2887/4885 |
| US-20040235917-A1 | Topical application of thiazolyl amides | TK1, TREH, SUCLG1 | CYP19A1 3550/4885SMN1; SMN2 4743/4885L3MBTL1 3954/4885 |
| US-20040006076-A1 | Thiazolyl amide derivatives | MAVS, EIF2AK2, SARS1 | CYP19A1 4839/4885SMN1; SMN2 4613/4885L3MBTL1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.